Hoe verhoudt CHE's PE Ratio zich tot zijn concurrenten?

CHE is een goede waarde op basis van zijn Price-To-Earnings Ratio (28.3x) vergeleken met het gemiddelde van gelijken (33.4x).

Hoe verhoudt CHE's PE Ratio zich tot andere bedrijven in de US Healthcare industrie?

CHE is duur op basis van de Price-To-Earnings -ratio ( 28.3 x) vergeleken met het US Healthcare -industriegemiddelde ( 24.4 x).

Wat is CHE's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

CHE is duur op basis van de Price-To-Earnings Ratio ( 28.3 x) vergeleken met de geschatte Fair Price-To-Earnings Ratio ( 25.6 x).

Wat is de reële prijs van CHE als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

CHE ( $571.31 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( $756.11 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is minder dan 20 % hoger dan de huidige aandelenkoers.

Chemed (NYSE:CHE) - Aandelenkoers, Nieuws & Analyse

CHE Overzicht aandelen

Chemed Corporation biedt hospice- en palliatieve zorgdiensten aan patiënten via een netwerk van artsen, gediplomeerde verpleegkundigen, thuiszorgassistenten, maatschappelijk werkers, geestelijken en vrijwilligers, voornamelijk in de Verenigde Staten. Meer informatie

CHE fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	1/6
Prestaties in het verleden	6/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 24.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 8.76% per jaar groeien

De winst groeide het afgelopen jaar met 23.4%

Risicoanalyse

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Chemed Corporation Concurrenten

CorVel

NasdaqGS:CRVL

US$6.2b

DaVita

NYSE:DVA

US$13.6b

Option Care Health

NasdaqGS:OPCH

US$4.0b

Quest Diagnostics

NYSE:DGX

US$18.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Chemed
Historische aandelenkoersen
Huidige aandelenkoers	US$571.31
52 Week Hoogtepunt	US$654.62
52 Week Laag	US$523.33
Bèta	0.46
11 maand verandering	6.63%
3 maanden verandering	-2.54%
1 Jaar Verandering	0.82%
33 jaar verandering	21.56%
5 jaar verandering	31.06%
Verandering sinds IPO	4,950.25%

Recent nieuws en updates

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 01

Recent updates

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 01

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

Oct 29

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

May 14

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Apr 26

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Mar 01

The Price Is Right For Chemed Corporation (NYSE:CHE)

Dec 30

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Nov 30

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Oct 26

Chemed - Showcasing Why It's So Reliable

Aug 26

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

Aug 13

Is Chemed Corporation (NYSE:CHE) Worth US$521 Based On Its Intrinsic Value?

Aug 01

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Jul 14

Chemed (NYSE:CHE) Has A Rock Solid Balance Sheet

Jun 07

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Apr 09

Chemed Q4 2022 Earnings Preview

Feb 22

Chemed Corporation: Long-Term Tailwinds, But Remains A Hold

Feb 14

Is Chemed (NYSE:CHE) Using Too Much Debt?

Jan 05

Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

Dec 17

Chemed declares $0.38 dividend

Nov 04

Chemed Q3 2022 Earnings Preview

Oct 28

Rendement voor aandeelhouders

	CHE	US Healthcare	US Markt
7D	0.06%	1.9%	0.5%
1Y	0.8%	4.6%	30.7%

Rendement versus industrie: CHE presteerde slechter dan de US Healthcare -sector, die het afgelopen jaar een rendement van 4.6 % opleverde.

Rendement versus markt: CHE presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.7 % opleverde.

Prijsvolatiliteit

Is CHE's price volatile compared to industry and market?
CHE volatility
CHE Average Weekly Movement	4.2%
Healthcare Industry Average Movement	7.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: CHE heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van CHE is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1970	15,087	Kevin McNamara	www.chemed.com

Chemed Corporation biedt hospice- en palliatieve zorgdiensten aan patiënten via een netwerk van artsen, geregistreerde verpleegkundigen, thuiszorgassistenten, maatschappelijk werkers, geestelijken en vrijwilligers, voornamelijk in de Verenigde Staten. Het bedrijf is actief in de segmenten VITAS en Roto-Rooter. Het bedrijf biedt loodgieterswerk, afvoerreiniging, uitgraving, waterherstel en andere aanverwante diensten aan particuliere en commerciële klanten via eigen vestigingen, onafhankelijke aannemers en franchisenemers.

Chemed Corporation Samenvatting

Hoe verhouden de winst en inkomsten van Chemed zich tot de beurswaarde?
CHE fundamentele statistieken
Marktkapitalisatie	US$8.53b
Inkomsten(TTM)	US$301.73m
Inkomsten(TTM)	US$2.38b

28.3x

Koers/Winstverhouding

3.6x

P/S-verhouding

Is CHE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CHE resultatenrekening (TTM)
Inkomsten	US$2.38b
Kosten van inkomsten	US$1.53b
Brutowinst	US$847.80m
Overige uitgaven	US$546.06m
Inkomsten	US$301.73m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	20.21
Brutomarge	35.66%
Nettowinstmarge	12.69%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CHE op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.4%

Huidig dividendrendement

8%

Uitbetalingsratio

Betaalt CHE een betrouwbaar dividend?

Zie CHE dividendgeschiedenis en benchmarks

Wanneer moet je CHE kopen om een aanstaand dividend te ontvangen?
Chemed dividenddata
Ex Dividend Datum	Nov 18 2024
Betaaldatum dividend	Dec 06 2024
Dagen tot Ex-dividend	12 days
Dagen tot dividendbetaaldatum	6 days

Betaalt CHE een betrouwbaar dividend?

Zie CHE dividendgeschiedenis en benchmarks

CHE Overzicht aandelen

Beloningen

Risicoanalyse

Chemed Corporation Concurrenten

NasdaqGS:CRVL

US$6.2b

NYSE:DVA

US$13.6b

NasdaqGS:OPCH

US$4.0b

NYSE:DGX

US$18.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

CEO, President & Director notifies of intention to sell stock

Executive Vice President recently sold US$566k worth of stock

Third quarter dividend of US$0.50 announced

Chemed Corporation Declares Quarterly Dividend, Payable on December 6, 2024

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings: EPS misses analyst expectations

Recent updates

CEO, President & Director notifies of intention to sell stock

Executive Vice President recently sold US$566k worth of stock

Third quarter dividend of US$0.50 announced

Chemed Corporation Declares Quarterly Dividend, Payable on December 6, 2024

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings: EPS misses analyst expectations

Now 29% undervalued after recent price drop

Chemed Corporation Revises Consolidated Earnings Guidance for the Full Year 2024

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

CEO, President & Director recently sold US$1.2m worth of stock

Chemed Corporation to Report Q3, 2024 Results on Oct 29, 2024

Executive Vice President recently sold US$975k worth of stock

Executive Vice President exercised options and sold US$1.6m worth of stock

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Chemed Remains A Buy On Long-Term Economics

VP & Director notifies of intention to sell stock

Second quarter dividend increased to US$0.50

Chemed Corporation Declares Quarterly Dividend, Payable on August 30, 2024

Executive Vice President recently sold US$1.1m worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation's (NYSE:CHE) Shares May Have Run Too Fast Too Soon

Chemed Corporation to Report Q2, 2024 Results on Jul 24, 2024

CEO, President & Director recently sold US$816k worth of stock

CEO, President & Director notifies of intention to sell stock

First quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on June 18, 2024

Chemed: Growth Does Not Justify The Current Stock Price

CEO, President & Director recently sold US$2.3m worth of stock

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Chemed Corporation Reiterates Earnings Guidance for Full Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation, Annual General Meeting, May 20, 2024

New major risk - Revenue and earnings growth

Executive Vice President exercised options and sold US$3.8m worth of stock

Executive Vice President recently sold US$1.3m worth of stock

Chemed Corporation to Report Q1, 2024 Results on Apr 24, 2024

Price target increased by 10% to US$690

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Now 22% overvalued after recent price rise

Third quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on March 15, 2024

Chemed Corporation to Report Q4, 2023 Results on Feb 27, 2024

The Price Is Right For Chemed Corporation (NYSE:CHE)

Chemed Corporation Appoints Michael D. Witzeman as Chief Financial Officer, Effective January 1, 2024

CEO, President & Director recently sold US$859k worth of stock

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Executive Vice President recently sold US$580k worth of stock

Executive VP & CFO notifies of intention to sell stock

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Executive VP & CFO exercised options to buy US$5.9m worth of stock.

CEO, President & Director recently sold US$1.7m worth of stock

Chemed Corporation Provides Earnings Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Chemed Corporation to Report Q3, 2023 Results on Oct 25, 2023